{
  "source": "PA-Notification-Akeega.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1421-2\nProgram Prior Authorization/Notification\nMedication Akeega™ (niraparib and abiraterone acetate)\nP&T Approval Date 11/2023, 11/2024\nEffective Date 2/1/2025\n1. Background:\nAkeega (niraparib and abiraterone acetate) is a combination of niraparib, a poly (ADP-ribose)\npolymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with\nprednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-\nmutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for\ntherapy based on an FDA-approved test for Akeega.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Akeega will be approved based on the following criterion:\na. Member is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Initial Authorization\n1. Akeega will be approved based on all of the following criteria:\na. Diagnosis of metastatic castration-resistant prostate cancer (mCRPC)\n-AND-\nb. Deleterious or suspected deleterious BRCA-mutated (BRCAm)\n-AND-\nc. Used in combination with prednisone\n© 2024 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\nC. Reauthorization\n1. Akeega will be approved based on the following criterion:\na. Patient does not show evidence of progressive disease while on Akeega therapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment",
    "on:\na. Patient does not show evidence of progressive disease while on Akeega therapy\nAuthorization will be issued for 12 months.\nD. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Akeega [package insert]. Horsham, PA: Janssen Biotech, Inc.; August 2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed\nSeptember 26, 2024.\nProgram Prior Authorization/Notification - Akeega (niraparib and abiraterone\nacetate)\nChange Control\n11/2023 New program\n11/2024 Annual review. No changes to criteria. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}